Dark Streaming/Mobile Old Site Home Daily Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:25:28 EDT Tue 28 Mar 2023
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:ACHL from 2022-03-29 to 2023-03-28 - 19 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2023-03-07 07:00U:ACHLNews ReleaseAchilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights
2022-12-20 08:30U:ACHLNews ReleaseAchilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-06 06:00U:ACHLNews ReleaseAchilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022
2022-11-30 18:05U:ACHLNews ReleaseAchilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
2022-11-22 08:00U:ACHLNews ReleaseAchilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method
2022-11-08 07:00U:ACHLNews ReleaseAchilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
2022-10-06 08:30U:ACHLNews ReleaseAchilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy
2022-08-09 07:00U:ACHLNews ReleaseAchilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
2022-07-21 08:00U:ACHLNews ReleaseAchilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing
2022-06-30 08:00U:ACHLNews ReleaseAchilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board
2022-06-21 08:30U:ACHLNews ReleaseAchilles Therapeutics Recognized with the 2022 PING Innovation Award
2022-05-10 07:00U:ACHLNews ReleaseAchilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
2022-05-09 07:00U:ACHLNews ReleaseAchilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma
2022-05-04 08:00U:ACHLNews ReleaseAchilles Therapeutics Appoints Bernhard Ehmer to Board of Directors
2022-05-03 08:00U:ACHLNews ReleaseAchilles Therapeutics to Present at Upcoming Conferences
2022-04-12 07:30U:ACHLNews ReleaseThe Center for Breakthrough Medicines (CBM) Strikes Multi-Year Deal with UK Cell Therapy Powerhouse
2022-04-12 07:30U:ACHLNews ReleaseAchilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US
2022-04-05 08:00U:ACHLNews ReleaseAchilles Therapeutics to Present at Upcoming Conferences
2022-04-04 08:00U:ACHLNews ReleaseAchilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting